^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CLN-619

    i
    Other names: CLN-619, CLN 619, CLN619
    Associations

    News

    Trials
    Company:
    Cullinan Therap
    Drug class:
    γδ TCR modulator, MICA agonist, MICB agonist, NKG2D stimulant
    Related drugs:
    Associations

    News

    Trials
    10d
    CLN-619-001: A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=440, Active, not recruiting, Cullinan Therapeutics Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • Datroway (datopotamab deruxtecan-dlnk) • CLN-619
    3ms
    A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, Cullinan Therapeutics Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CLN-619
    7ms
    CLN-619, a MICA/B monoclonal antibody that promotes innate immune cell-mediated antitumor activity. (PubMed, J Immunother Cancer)
    CLN-619 inhibited the shedding of MICA/B to effectively restore cytotoxic signaling pathways in immune cells. Potent antitumor activity of CLN-619 as a monotherapy was observed in several preclinical models. Activity of CLN-619 required a functional Fcγ1 domain, suggesting the requirement of simultaneous engagement of NKG2D and cluster of differentiation 16A (CD16A) on immune cells for optimal cytotoxicity. The preclinical data reported here support the assessment of CLN-619 in patients with cancer.
    Journal
    |
    FCGR3A (Fc Fragment Of IgG Receptor IIIa) • MICA (MHC Class I Polypeptide-Related Sequence A) • MICB (MHC Class I Polypeptide-Related Sequence B) • NKG2D (killer cell lectin like receptor K1)
    |
    CLN-619
    over1year
    A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=30, Recruiting, Cullinan Therapeutics Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CLN-619
    over1year
    A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Cullinan Therapeutics Inc.
    New P1 trial
    |
    CLN-619
    over1year
    A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=410, Recruiting, Cullinan Oncology Inc. | Trial completion date: Mar 2026 --> Jun 2026 | Trial primary completion date: Sep 2025 --> Mar 2026
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    Keytruda (pembrolizumab) • CLN-619
    3years
    A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=410, Recruiting, Cullinan Oncology, LLC | N=148 --> 410
    Enrollment change • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    Keytruda (pembrolizumab) • CLN-619
    3years
    CLN-619, a clinical-stage MICA/B-specific IgG1 antibody which restores the MICA/B-NKG2D axis requires Fc function for potent anti-tumor activity (SITC 2022)
    Treatment was administered 2X weekly for four weeks intraperitoneal. Statistics were analyzed by one-way ANOVA adjusted for multiple comparisons.
    Clinical
    |
    MICA (MHC Class I Polypeptide-Related Sequence A) • MICB (MHC Class I Polypeptide-Related Sequence B) • NKG2D (killer cell lectin like receptor K1)
    |
    CLN-619
    over3years
    CLN-619, a clinical-stage MICA/MICB-specific IgG1 antibody, restores the MICA/MICB-NKG2D axis to promote NK-mediated tumor cell lysis (AACR 2022)
    Given the pan-cancer expression of MICA/MICB in both solid and hematological malignancies, CLN-619 is expected to have broad anti-tumor activity. CLN-619 is currently being investigated in a Phase 1 clinical trial for the treatment of patients with advanced solid tumors.
    Clinical
    |
    MICA (MHC Class I Polypeptide-Related Sequence A) • MICB (MHC Class I Polypeptide-Related Sequence B) • NKG2D (killer cell lectin like receptor K1)
    |
    CLN-619